Enterprise Value

442.8M

Cash

241.3M

Avg Qtr Burn

-43.04M

Short % of Float

28.43%

Insider Ownership

11.23%

Institutional Own.

99.68%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
YUPELRI® (revefenacin) Details
Chronic obstructive pulmonary disease

Phase 4

Data readout

TRELEGY ELLIPTA Details
Chronic obstructive pulmonary disease (COPD)

Approved

Quarterly sales

Approved

Quarterly sales

Phase 3

Data readout

Izencitinib (TD-1473) (GUT-SELECTIVE JAK INHIBITOR) Details
Inflammatory bowel disease, Inflammatory disease, Crohns disease, Ulcerative colitis

Phase 2/3

Update

Phase 2

Update

Phase 2

Update